IMPORTANT SAFETY INFORMATION:

INDICATIONS: The AVAR® (sodium sulfacetamide and sulfur) product family (AVAR® Cleanser, AVAR® LS Cleanser, AVAR-e® Emollient Cream, AVAR-e Green® Cream, AVAR-e® LS Emollient Cream, AVAR® Foam, AVAR® LS Foam) are prescription medicines used on the skin (topical) for the control of acne vulgaris, acne rosacea and seborrheic dermatitis. AVAR products contain sodium sulfacetamide, a sulfonamide antibiotic, which prevents bacteria from growing.

Important Safety Information

AVAR products are not for everyone. You should not use AVAR products if you:

  • are allergic to any ingredient in AVAR products. Ask your doctor if you are not sure.
  • have had a severe allergic reaction (e.g., severe rash, hives, difficulty breathing, swelling) to sulfonamide medicines or sulfur.
  • have kidney disease.

KEEP ALL AVAR PRODUCTS OUT OF THE REACH OF CHILDREN.

Before you use AVAR products, tell your doctor about all of your medical conditions, including if you:

  • are pregnant or planning to become pregnant. It is not known whether AVAR products can cause harm to the fetus.
  • are breastfeeding or plan to breastfeed. It is not known whether the ingredients in AVAR products can pass into breast milk.
  • have allergies to medicines, foods, or other substances.

AVAR PRODUCTS ARE FOR EXTERNAL USE ONLY. AVOID CONTACT WITH THE EYES. AVAR products should be used as directed by your doctor. Do not use them for other conditions. AVAR products should not be used in children younger than 12 years old; safety and effectiveness in these children have not been determined.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. You should tell your doctor if you are using silver-containing medicines, such as silver sulfadiazine.

AVAR products may cause serious side effects in some people, including:

  • severe allergic reactions. You should discontinue any AVAR product if the condition becomes worse, or if a rash develops in the area being treated or elsewhere. Seek medical attention right away if you develop signs or symptoms of a severe allergic reaction (rash, hives, itching, difficulty breathing, tightness in the chest, swelling of the mouth, face, lips, or tongue).
  • systemic lupus erythematosus. In one of these cases there was a fatal outcome. Discontinue the AVAR product immediately and contact your doctor right away if you experience arthritis (pain, stiffness or swelling in your joints), or fever or sores in your mouth develop.

Possible side effects of AVAR products include mild skin irritation or dryness. These are not all of the possible side effects of AVAR products. Tell your doctor if you have any side effect that bothers you or does not go away.

You may report negative side effects to Mission Pharmacal Company at 1-800-298-1087, or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

You have Successfully Subscribed!

IMPORTANT SAFETY INFORMATION:

INDICATIONS: UTIRA-C®(methenamine 81.6 mg, sodium phosphate monobasic 40.8 mg, phenyl salicylate 36.2 mg,methylene blue 10.8 mg, and hyoscyamine sulfate 0.12 mg) is indicated for the treatment of symptoms of irritative voiding, the relief of local symptoms (e.g., inflammation, hypermotility, pain) which accompany lower urinary tract infections, and for the relief of urinary tract symptoms caused by diagnostic procedures.

Important Safety Information

CONTRAINDICATIONS: Hypersensitivity to any of the ingredients is possible. Risk benefits should be carefully considered with certain medical conditions: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).

WARNINGS: Do not exceed recommended dosage. If rapid pulse, dizziness or blurring of vision occurs discontinue use immediately.

PRECAUTIONS:

UTIRA-C® should be used with caution in:

  • patients who are intolerant of belladonna alkaloids or salicylates.
  • patients with gastric ulcers. Delay in gastric emptying could complicate management.
  • pregnant women. It is not known whether UTIRA-C causes fetal harm or can affect reproductive capacity. Only use if clearly needed.
  • nursing mothers. Only use if clearly needed as methenamine and hyoscyamine are excreted in breast milk.
  • patients who require prolonged use. There have been no studies to establish the safety of long-term use in humans or animal studies to evaluate carcinogenic potential.
  • infants and young children who are especially susceptible to the toxic effects of belladonna alkaloids.
  • elderly patients as they may experience excitement, agitation, drowsiness or confusion.

ADVERSE REACTIONS: Adverse reactions associated with UTIRA-C include: rapid heartbeat, flushing, blurred vision, dizziness, drowsiness, difficult micturition, acute urinary retention, dry mouth, nausea, vomiting, and shortness of breath or trouble breathing.

Serious allergic reactions to this drug are rare. Patients should be instructed to seek immediate medical attention if they experience symptoms of a serious allergic reaction, including itching, rash, severe dizziness, swelling or trouble breathing.

This medication can cause urine and sometimes stools to turn blue to bluegreen. This effect is harmless and will subside after medication is stopped, however, patients should be advised.

DRUG INTERACTIONS: Because UTIRA-C can alter gastrointestinal motility and gastric emptying, it may decrease the absorption of other oral medications with concurrent use.

  • Urinary alkalizers and thiazide diuretics: may reduce the effectiveness of methenamine.
  • Antimuscarinics: may intensify antimuscarinic effects of hyoscyamine.
  • Antacids/antidiarrheals: may reduce absorption of hyoscyamine; may reduce effectiveness of methenamine. Doses of these medications should be spaced 1 hour apart from doses of UTIRA-C.
  • Antimyasthenics: concurrent use may further reduce intestinal motility; use caution.
  • Ketoconazole: concurrent use may result in marked reduction in ketoconazole. Advise patients to take UTIRA-C at least 2 hours after ketoconazole.
  • Monoamine oxidase (MAO) inhibitors: may intensify antimuscarinic side effects.
  • Opioids: may result in increased risk of severe constipation.
  • Sulfonamides: may increase the danger of crystalluria.

Please see full Prescribing Information.

You have Successfully Subscribed!